SYRE

+ Watchlist + Portfolio

Spyre Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $108.92
52-Week Range: $14.51 – $110.18
Market Cap: $9.50B
P/E (TTM): —
EPS (TTM): -1.90
Dividend Yield: —

Advanced Metrics

Price/Book: 9.94
PEG Ratio: —
Return on Equity: -22.98%
Return on Assets: -19.81%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 18.53
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-89.05M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $8.51B

SYRE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.33M	$886.00K	$0.00	$0.00
Research & Development	$58.58M	$89.50M	$162.79M	$171.65M
Selling, General & Admin	$28.53M	$39.95M	$45.78M	$47.91M
Operating Expenses	$87.11M	$129.45M	$208.57M	$219.56M
Operating Income	-$84.78M	-$128.56M	-$208.57M	-$219.56M
EBITDA	-$82.82M	-$127.82M	-$208.57M	-$219.56M
Pretax Income	-$83.95M	-$338.82M	-$207.97M	-$155.22M
Income Tax	-$136.00K	-$26.00K	$51.00K	-$15.00K
Net Income	-$83.81M	-$338.79M	-$208.02M	—
Diluted EPS	-24.75	-13.76	-3.18	-1.98
Diluted Shares	3.37M	6.90M	47.03M	64.06M

SYRE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.86M	$188.89M	$89.42M	$85.72M
Receivables	$375.00K	$0.00	—	—
Current Assets	$62.26M	$341.53M	$608.47M	$777.78M
Total Assets	$71.14M	$341.86M	$608.48M	$777.78M
Current Liabilities	$14.66M	$31.98M	$54.06M	$58.69M
Total Debt	$4.63M	$0.00	—	—
Total Liabilities	$20.84M	$157.84M	$90.68M	$62.55M
Retained Earnings	-$425.62M	-$764.41M	-$972.43M	-$1.13B
Shareholders' Equity	$50.30M	$184.02M	$517.80M	$715.24M
Working Capital	$47.60M	$309.55M	$554.41M	$719.10M

SYRE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$80.14M	-$99.91M	-$157.41M	-$169.25M
Capital Expenditure	-$38.00K	—	—	—
Free Cash Flow	-$80.18M	-$99.91M	-$157.41M	-$169.25M
Depreciation & Amortisation	$1.96M	$744.00K	$0.00	$0.00
Stock-Based Compensation	$7.11M	$25.68M	$44.83M	$37.61M
Investing Cash Flow	$57.01M	-$108.39M	-$353.29M	-$143.47M
Financing Cash Flow	$42.68M	$361.08M	$410.91M	$309.02M
Net Change in Cash	$19.54M	$152.77M	-$99.79M	-$3.70M

SYRE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$41.62M	$40.15M	$45.25M	$44.64M	$60.41M
Selling, General & Admin	$11.94M	$11.79M	$11.64M	$12.53M	$15.23M
Operating Expenses	$53.57M	$51.94M	$56.89M	$57.17M	$75.64M
Operating Income	-$53.57M	-$51.94M	-$56.89M	-$57.17M	-$75.64M
EBITDA	-$53.57M	-$51.94M	-$56.89M	-$57.17M	-$75.64M
Pretax Income	-$44.79M	-$36.72M	-$11.18M	-$62.53M	-$69.00M
Income Tax	-$15.00K	$0.00	$0.00	$0.00	$0.00
Net Income	-$44.77M	-$36.72M	-$11.18M	-$62.53M	-$69.00M
Diluted EPS	-0.60	-0.60	-0.18	-0.70	-0.74
Diluted Shares	60.27M	60.70M	60.78M	75.09M	78.55M

SYRE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$48.49M	$81.66M	$64.90M	$85.72M	$97.19M
Current Assets	$569.77M	$538.83M	$504.60M	$777.78M	$763.95M
Total Assets	$569.78M	$538.83M	$504.60M	$777.78M	$763.95M
Current Liabilities	$70.68M	$83.06M	$46.27M	$58.69M	$85.16M
Total Liabilities	$87.17M	$83.06M	$49.50M	$62.55M	$93.14M
Retained Earnings	-$1.02B	-$1.05B	-$1.07B	-$1.13B	-$1.20B
Shareholders' Equity	$482.61M	$455.77M	$455.10M	$715.24M	$670.81M
Working Capital	$499.09M	$455.77M	$458.33M	$719.10M	$678.79M

SYRE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$40.99M	-$46.56M	-$37.12M	-$44.58M	-$57.37M
Free Cash Flow	-$40.99M	-$46.56M	-$37.12M	-$44.58M	-$57.37M
Stock-Based Compensation	$8.86M	$9.38M	$9.57M	$9.81M	$12.81M
Investing Cash Flow	-$61.00K	$79.00M	$25.00M	-$247.41M	$56.58M
Financing Cash Flow	$125.00K	$731.00K	-$4.64M	$312.81M	$12.26M
Share Repurchases	-$117.00K	$0.00	—	—	—
Net Change in Cash	-$40.93M	$33.17M	-$16.76M	$20.82M	$11.46M

Market Snapshot

About

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immunological and inflammatory diseases. The company is advancing a pipeline of product candidates targeting areas of significant unmet medical need. Spyre Therapeutics aims to bring novel treatment options to patients with serious immune-mediated conditions.